Further, we assessed the efficacy of PRDM1 and NR4A3 single KO or PRDM1/NR4A3 double KO mesothelin-directed CAR T-cells in an in vivo model of highly resistant pancreatic adenocarcinoma incorporating AsPC1 tumor cells expressing endogenous mesothelin (fig. The gene discussed is MSLN; the disease is pancreatic adenocarcinoma.